What is MS Phase 3 Laquinimod MS-LAQ-301?

Category: Others

false

NCT00509145 is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with Relapsing Remitting Multiple Sclerosis. Other Study ID Numbers include MS-LAQ-301, EUDRACT 2007-003226-19.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple sclerosis 2 1
Doctor recommendation 1 2
Glaucoma 1 2
Vertigo 1 2

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
3

Commonly reported side effects and conditions associated with MS Phase 3 Laquinimod MS-LAQ-301

Side effect Patients
Back pain 1

Dosages

Based on patients currently using MS Phase 3 Laquinimod MS-LAQ-301

Dosage Patients
0.6 mg daily 1

Why patients stopped taking MS Phase 3 Laquinimod MS-LAQ-301

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped using MS Phase 3 Laquinimod MS-LAQ-301

Duration

Currently using MS Phase 3 Laquinimod MS-LAQ-301

Duration Patients
5 - 10 years 1

Stopped using MS Phase 3 Laquinimod MS-LAQ-301

Duration Patients
2 - 5 years 1
Adherence
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 1
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 3
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 0
Last updated:
There are no evaluations for MS Phase 3 Laquinimod MS-LAQ-301.